By literally freezing prostate cancer cells to death, radiologists can effectively treat prostate cancer in some patients while reducing complication rates, preliminary results of a study show. The new procedure, trans- rectal ultrasound-guided
By literally freezing prostate cancer cells to death, radiologistscan effectively treat prostate cancer in some patients while reducingcomplication rates, preliminary results of a study show. The newprocedure, trans- rectal ultrasound-guided cryoablation, alsocosts less than traditional prostate cancer treatments, the studyindicates.
Of the 310 men treated with the technique so far, 90% have hadnegative biopsies, said Dr. Duke Bahn, chair of the Departmentof Radiology at Crittenton Hospital in Rochester, Michigan. Follow-upof these patients ranged from 3 months to 2 years, Dr. Bahn toldthe American Roentgen Ray Society at its annual meeting in Washington,D.C.
Patients with cancer confined to the prostate gland or those whosecancer has spread near the gland are candidates for the freezingprocedure, said Dr. Bahn. Probes are inserted through small skinpunctures into the prostate gland. Liquid nitrogen is circulatedthrough the probes and the entire prostate is frozen. When theprostate thaws, the cells rupture and die, he said. "Thefreezing process is carefully monitored by high resolution ultrasoundto avoid injuries to adjacent organs," said Dr. Bahn. Patientsusually are only in the hospital overnight, and they can returnto their normal routine in about 2 weeks.
The cost of cryoablation is about one-third to one-half that ofsurgery or radiation therapy, Dr. Bahn noted. Complication ratesappear to be much lower than rates associated with surgery. Forexample, incontinence occurs in at least 30% of patients who undergosurgery. "Our incontinence rate is only 1%," said Dr.Bahn.
The cryoablation procedure can be repeated if it fails, said Dr.Bahn. Patients also can choose to undergo radiation therapy orsurgery if cryoablation proves ineffective, he added.
"We are very optimistic about this procedure," saidDr. Bahn. However, he cautioned, long-term clinical trials needto be done to determine whether this treatment increases overallsurvival. Transrectal ultrasound-guided cryoablation is availablein about 100 institutions across the United States.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.